Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Premade Virus Particles
Ready-to-Use | High Titer | Versatile Applications
Premade AAV, adenovirus, lentivirus particles, safe, stable, in stock.
Virus-Like Particles (VLPs)
Stable | Scalable | Customizable
Advanced VLPs for vaccine development (Chikungunya, Dengue, SARS-CoV-2), gene therapy (AAV1 & AAV9), and drug screening (SSTR2, CCR5).
Oligonucleotide Products
Precise | High Yield | Tailored Solutions
Accelerate your research with cost-effective LncRNA qPCR Array Technology.
RNA Interference Products
Targeted | Potent | High Specificity
Human Druggable Genome siRNA Library enables efficient drug target screening.
Recombinant Drug Target Proteins
Authentic | Versatile | Accelerated
Providing functional, high-purity recombinant proteins—including membrane proteins and nanodiscs—to overcome bottlenecks in drug screening and target validation.
Clones
Validated | Reliable | Comprehensive Collection
Ready-to-use clones for streamlined research and development.
Kits
Complete | Convenient | High Sensitivity
Chromogenic LAL Endotoxin Assay Kit ensures precise, FDA-compliant endotoxin quantification for biosafety testing.
Enzymes
Purified | Stable | Efficient
Powerful Tn5 Transposase for DNA insertion and random library construction.
Aptamers
Highly Specific | Robust | Versatile
Aptamers for key proteins like ACVR1A, Akt, EGFR, and VEGFR.
Adjuvants
Enhancing | Synergistic | Effective
Enhance immune responses with high-purity, potent CpG ODNs.
Laboratory Equipment
Innovative | Reliable | High-Precision
Effortlessly streamline DNA extraction with CB™ Magnetic-Nanoparticle Systems.
Stable Cell Line Generation
Reliable | Scalable | Customizable
Fast proposals, regular updates, and detailed reports; strict quality control, and contamination-free cells; knockout results in 4-6 weeks.
Target-based Drug Discovery Service
Innovative | Comprehensive | Efficient
Target identification, validation, and screening for drug discovery and therapeutic development.
Custom Viral Service
Versatile | High-Yield | Safe
Unbeatable pricing, fully customizable viral packaging services (covering 30,000+ human genes, 200+ mammals, 50+ protein tags).
Custom Antibody Service
Precise | Flexible | Efficient
End-to-end antibody development support, from target to validation, enabling clients to rapidly obtain application-ready antibodies.
Antibody-Drug Conjugation Service
Integrated | Controlled | Translational
Comprehensive solutions covering design, development, and validation to ensure conjugated drugs with consistent quality and clinical potential.
Protein Degrader Service
Efficient | High-Precision | Advanced Therapeutics
Harness the power of protein degraders for precise protein degradation, expanding druggable targets and enhancing therapeutic effectiveness for cutting-edge drug discovery.
Nucleotides Service
Accurate | Flexible | High-Quality
Custom synthesis of oligonucleotides, primers, and probes for gene editing, PCR, and RNA studies.
Custom RNA Service
Custom RNA ServicePrecise | Flexible | GMP-ReadyCustom
RNA design, synthesis, and manufacturing—covering mRNA, saRNA, circRNA, and RNAi. Fast turnaround, rigorous QC, and seamless transition from research to GMP production.
Custom Libraries Construction Service
Comprehensive | High-throughput | Accurate
Custom cDNA, genomic, and mutagenesis libraries for drug discovery, screening, and functional genomics.
Gene Editing Services
Precise | Efficient | Targeted
Gene editing solutions for gene editing, knockouts, knock-ins, and customized genetic modifications. Integrated multi-platform solutions for one-stop CRISPR sgRNA library synthesis and gene screening services
Microbe Genome Editing Service
Precise | Scalable | Customizable
Enhance microbial productivity with advanced genome editing using Rec-mediated recombination and CRISPR/Cas9 technologies.
Biosafety Testing Service
Reliable | Comprehensive | Regulated
Complete biosafety testing solutions for gene therapy, viral vectors, and biologics development.
Plant Genetic Modification Service
Advanced | Sustainable | Tailored
Genetic modification for crop improvement, biotechnology, and plant-based research solutions.
Plant-based Protein Production Service
Efficient | Scalable | Customizable
Plant-based protein expression systems for biopharmaceuticals, enzyme production, and research.
Aptamers Service
Innovative | Fast | Cost-Effective
Revolutionizing drug delivery and diagnostic development with next-generation high-throughput aptamer selection and synthesis technologies.
CGT Biosafety Testing
Comprehensive | Accurate | Regulatory-compliant
Internationally certified evaluation system for biologics, gene therapies, nucleic acid drugs, and vaccines.
Pandemic Detection Solutions
Rapid | Precise | Scalable
Balancing accuracy, accessibility, affordability, and rapid detection to safeguard public health and strengthen global response to infectious diseases.
cGMP Cell Line Development
Reliable | Scalable | Industry-leading
Stable expression over 15 generations with rapid cell line development in just 3 months.
Supports adherent and suspension cell lines, offering MCB, WCB, and PCB establishment.
GMP mRNA Production
Efficient | Scalable | Precise
Scalable mRNA production from milligrams to grams, with personalized process design for sequence optimization, cap selection, and nucleotide modifications, all in one service.
GMP Plasmid Production
High Quality | Scalable | Regulatory-compliant
Our plasmid production services span Non-GMP, GMP-Like, and GMP-Grade levels, with specialized options for linearized plasmids.
GMP Viral Vector Manufacturing
Scalable | High Yield | Quality-driven
Advanced platforms for AAV, adenovirus, lentivirus, and retrovirus production, with strict adherence to GMP guidelines and robust quality control.
AI-Driven Gene Editing and Therapy
Innovative | Precision | Transformative
AI-powered one-click design for customized CRISPR gene editing strategy development.
AI-Antibody Engineering Fusion
Next-Generation | Targeted | Efficient
AI and ML algorithms accelerate antibody screening and predict new structures, unlocking unprecedented possibilities in antibody engineering.
AI-Driven Enzyme Engineering
Smart | Efficient | Tailored
High-throughput enzyme activity testing with proprietary datasets and deep learning models for standardized and precise enzyme engineering design.
AI-Enhanced Small Molecule Screening
Predictive | Efficient | Insightful
Leverage AI to uncover hidden high-potential small molecules, prioritize leads intelligently, and reduce costly trial-and-error in early drug discovery.
AI-Driven Protein Degrader Drug Development
Innovative | Targeted | Accelerated
Use AI-guided design to optimize protein degraders, addressing design complexity and enhancing efficacy while shortening development timelines.
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
Recent Progress
It has already been indicated by the researchers that human peripheral and intestinal myeloid-derived cells express LACC1. More specifically, LACC1 is expressed in both the cytoplasm and mitochondria. In addition to stimulating the Nod2(a kind of receptor) of human macrophages, LACC1 also associates with the Nod2-signalling complex. Moreover, LACC1 is critical for optimal Nod2-induced signalling, mitochondrial ROS (mtROS) production, cytokine secretion and bacterial clearance.
Recent discovery further proved that variants of LACC1 could play a role in the formation of the recessive form of juvenile arthritis. It appears that age of onset tend to be earlier in patients with LACC1 pathogenic or likely pathogenic variants. Based on the common knowledge on Mendelian inheritance, for the first time, the finding that affected siblings in family E do not share genotypes suggests genetic heterogeneity in familial juvenile arthritis. Further results indicate that pathogenic variants of LACC1 can cause familial juvenile arthritis. Due to the high clinical variability of juvenile arthritis observed, researchers came to propose it can be beneficial for patients and families to screen patients with JIA(Juvenile idiopathic arthritis), especially those with very early onset, for LACC1 variants.
It has been reported that genetic variation at the locus of LACC1 consistently influence the risk of Crohn's disease (CD) and leprosy. Recently, a missense mutation of LACC1 was found both in patients with monogenic forms of CD and systemic juvenile idiopathic arthritis. Thus the researchers proposed that LACC1 single nucleotide polymorphisms (SNPs) are associated with CD and juvenile idiopathic arthritis (JIA, non-systemic), also the ulcerative colitis (UC). UC is another major form of inflammatory bowel disease. To test this hypothesis, investigators selected 11 LACC1 tagged with SNPs, and tested their impact on disease risk in 3855 Swedish individuals from three case-control cohorts of CD, UC and JIA. Findings detected expanded previous results for CD also to UC and JIA.
Considering that the pathological basis of sJIA is still somewhat controversial, especially arguments for both auto-immune and auto-inflammatory etiologies both exist. In order to identify the cause of an autosomal recessive form of sJIA, researchers investigated 13 sJIA patients from 5 consanguineous families, selected from the southern region of Saudi Arabia. Linkage, homozygosity mapping and whole exome sequencing were adopted to identify the disease associated gene and mutation. Linkage analysis revealed that localized sJIA to a region on 13 with a maximal LOD score of 11.33, indicating the strongest linkage to date for this disorder. Homozygosity mapping decreased the critical interval to a 1.02 Mb region, which is defined proximally by rs9533338 and distally by rs9595049. As for whole exome sequencing, a homoallelic missense mutation in LACC1 was identified. It encodes the enzyme (multi-copper oxidoreductase) domain containing 1. Sanger sequencing further confirmed this mutation and segregated with disease in all 5 families. These findings taken together, provide strong genetic evidence that associates mutation of LACC1 with sJIA in the studied families.
A Chinese genome-wide association study (GWAS) depicted novel genes and pathways associated with leprosy susceptibility. Given that it is only partially replicated by independent studies in different ethnicities, researchers described the results of a validation and replication study of the Chinese GWAS in Brazilians, through a stepwise strategy. This study involved two family-based and three independent case-control samples, with 3,614 individuals enrolled. A family-based sample for 36 tag single-nucleotide polymorphisms (SNPs) of five genes was genotyped. These genes are located in four different candidate loci: CCDC122-LACC1, NOD2, TNFSF15 and RIPK2. Association between leprosy and tag SNPs at NOD2 (rs8057431) and CCDC122-LACC1 (rs4942254) was then copied in three additional and independent samples. Findings from these data suggest the NOD2 pathway play a role in the regulation of leprosy susceptibility, across diverse populations. It is suggested by the investigators that LACC1 constitutively associates with succinate dehydrogenase (SDH) subunit A, and promotes pattern recognition receptor (PRR)-induced SDH activity. Relative to LACC1 Ile254, cells transfected with Crohn's disease-risk LACC1 Val254 or LACC1 with mutations of the nearby histidines have decreased PRR-induced outcomes. Relative to LACC1 Ile254 carriers, Val254 disease-risk carrier macrophages indicate reduced PRR-induced mtROS signalling, cytokine secretion and bacterial clearance. These results suggest that LACC1 is critical for promoting PRR-induced outcomes, and this outcome could be attenuated by the LACC1 disease-risk variant.
References:
Contact us today for a free consultation with the scientific team and discover how Creative Biogene can be a valuable resource and partner for your organization.
Inquiry
Copyright © Creative Biogene. All rights reserved.